Dorthe Grønnegaard Mejer joins FluoGuide A/S as Vice President of Clinical Development
Copenhagen, Denmark, 30 June 2020 – FluoGuide A/S (“FluoGuide” or “the Company”) has recruited Dorthe Grønnegaard Mejer as VP of Clinical Development.
The clinical development of FG001 for use to guide surgery of aggressive brain cancer (glioblastoma) can be very short until approval. In order to secure maximal usefulness of the first clinical trial commencing this fall, the Company has recruited Dorthe Grønnegaard Mejer to the position of VP of Clinical Development. Dorthe Grønnegaard Mejer has a Master of Science in Pharmaceutical Sciences from Copenhagen University. She has previously held several positions across different clinical development disciplines as well as positions within clinical oncology development in smaller biotech companies. In her role as VP of Clinical Development, Dorthe Grønnegaard Mejer is responsible for a fast clinical development of FG001 to approval and thereby to a broad clinical use to the benefit of patients with glioblastoma. The recently announced EU grant on EUR 2.5 million allows FluoGuide to establish this key function in-house and build knowledge in preparation for the Company’s important pivotal phase III trial for FG001 in glioblastoma.
“We are very pleased to have Dorthe joining the development team at FluoGuide. We will continue to expand the team as we advance FG001 through clinical development to approval”, says Grethe Rasmussen, CDO of FluoGuide.
The design of the first clinical trial for FG001 in glioblastoma has been significantly improved and many aspects of the pivotal phase II/III clinical trial design have already been discussed in detail. Dorthe with team are working very hard to finish the Clinical Trial Application for submission within a week. FluoGuide will continue to update on the clinical trial, its design and its potential outcome over the summer.
“I am very excited about this new position being both professionally challenging and with a great potential for the patients with cancer”, says Dorthe Grønnegaard Mejer.
For further information, please contact:
Morten Albrechtsen, CEO
M: +45 24 25 62 66
FluoGuide’s primary focus is to maximize surgical outcomes in oncology. The Company’s first product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide’s products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, these improvements will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. The Company is planning a proof-of-concept clinical study (phase I/II) to demonstrate the effect of FG001 in patients with glioblastoma.
This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 954904.